ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NBIX vs BNTX // GROSS PROFIT MARGIN

Neurocrine Biosciences Inc. (NASDAQ) VS. BioNTech SE (NASDAQ) • 15-METRIC TALLY: NBIX 10 — BNTX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NBIX VS. BNTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NBIX BNTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 15.70% 9.90% +5.80 NBIX /roic <GO>
EV/EBITDA & P/E Valuation 22.8x 21.0x +1.80 BNTX /valuation <GO>
Free Cash Flow Yield 5.03% 2.21% +2.82 NBIX /fcf-yield <GO>
Operating Margin 21.60% 13.90% +7.70 NBIX /operating-margins <GO>
Net Profit Margin 16.70% 10.90% +5.80 NBIX /net-margins <GO>
Revenue Growth (YoY) 21.40% 14.30% +7.10 NBIX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.13 3.74 +4.39 NBIX /balance-sheet <GO>
Piotroski F-Score Quality 9/9 8/9 +1.00 NBIX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.1 43.4 +12.70 NBIX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.13 1.02 +0.11 NBIX /macro-sensitivity <GO>
Forward P/E Multiple 26.1x 27.6x -1.50 NBIX /forward-pe <GO>
Enterprise Scale & Market Cap $14.88B $22.39B -$7.51B BNTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NBIX REV BNTX REV NBIX GROSS % BNTX GROSS % NBIX FCF BNTX FCF
FY 2025 $2.86B — 98.2% — $748.7M —
FY 2024 $2.36B — 98.6% — $557.2M —
FY 2023 $1.89B — — — $305.0M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NBIX // BETA 1.13
BNTX // BETA 1.02